Across TCGA pan-cancer cohorts, SPI1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SPI1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in mesothelioma (MESO), where higher SPI1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPI1 expression acts as an unfavorable survival marker.
MESO, COAD, and UCEC are the cancer types where SPI1 Mutation most reproducibly stratifies survival.